Hand in Hand, Igniting a New Chapter in Science: Strategic Collaboration between Dong阳光 Pharma and DP Technology to Co-create the Future

Nov 09, 2024 15:18 CST Updated 15:18

DP Technology

Simulation R&D Platform Developer

The 2024 AI for Science Forum was held in Beijing from November 4 to November 6. This summit brought together organizations in the "industry, academia, research, and application" fields of AI for Science to jointly explore the application and future of AI in scientific research. The forum created a dialogue platform for scientists and industry participants to identify key issues in scientific research, seize new opportunities, promote interdisciplinary integration, and find the best path for practical implementation through exchange.

Guangdong HEC Pharm Co., Ltd. (hereinafter referred to as HEC Pharm) was invited as a keynote sharing enterprise to participate in this summit. Following the establishment of the AI4S Joint Laboratory by HEC Pharm and DP Technology in August, the two parties officially signed a comprehensive strategic cooperation agreement at this summit, aiming to deeply explore how artificial intelligence can effectively promote the practical implementation of drug research and development, and jointly advance new trends in the development of the biopharmaceutical industry.

On-site photos of the 2024 Scientific Intelligence Summit

At the AI4S Industry and Practice Forum during the Scientific Intelligence Summit, Dr. Zhang Yingjun, Chairman of Guangdong Dongyangguang Pharmaceutical Co., Ltd., stated in the keynote sharing session:

The R&D platform of Dongyang Guangya Pharmaceutical has fully covered the entire process of R&D for both large and small molecule drugs, from target validation to industrialization. To continuously promote technological advancement and industrial upgrading, Dongyang Guangya Pharmaceutical will keep optimizing its technical platforms, carry out iterative upgrades, and actively explore diversified drug forms, injecting new vitality and strong momentum into innovative drug development. As a leading enterprise driven by innovation, Dongyang Guangya Pharmaceutical has built a powerful AIDD platform with strong computing capabilities, providing solid technical support for drug R&D. This platform integrates multiple advanced AI tools, significantly improving R&D efficiency, demonstrating excellent performance and effectiveness, and further expanding the boundaries and possibilities of drug R&D. In typical projects, the application of AI technology has enabled Dongyang Guangya Pharmaceutical to greatly shorten the PCC screening time, securing a valuable time window for new drug development.

Looking ahead, Dongyangguang Group has meticulously laid out its plans, establishing a strategic blueprint centered on "technological innovation and healthy living," with AI-empowered R&D as a key pillar of this vision. Dongyangguang Pharmaceutical is committed to building a high-quality chemical knowledge database at its core, which will serve as the foundation for an AI-powered intelligent computing platform in the pharmaceutical field. The aim is to create a new industry ecosystem that deeply integrates new drug development with AI technology.

Dr. Zhang Yingjun emphasized that through this series of forward-looking and innovative initiatives, Dongyangguang Group will collaborate with numerous partners to jointly cultivate a vibrant innovation ecosystem, continuously unleashing the power of innovation-driven approaches to provide comprehensive empowerment for drug research and development, lead the AI + drug R&D industry, and become China's most influential AI drug research institute.

Under the guidance of the construction plan for the joint laboratory, Dongyang Guangya Pharmaceutical will further deepen its close collaboration with partners such as DP Technology. Focusing on high-value R&D scenarios and technical bottlenecks in the biopharmaceutical field, they aim to drive technological innovation from the source to industrial implementation, forming a complete closed loop. Together, they will explore the transformation and validation of cutting-edge AI technologies in the biopharmaceutical industry. Both parties will work hand in hand to accelerate the drug development process, bringing more hope and good news to patients worldwide, and jointly promoting the vigorous development of the pharmaceutical and healthcare industry.

Figure 2: Dongyangguang Pharmaceutical Vertical AI Expert Model

Guangdong Dongyangguang Pharmaceutical Co., Ltd. (hereinafter referred to as Dongyangguang Pharma), as the leading company in China's anti-influenza field, its anti-influenza drug Kewe^®As the leading brand of Oseltamivir Phosphate, it received three certifications from the internationally authoritative institution Frost & Sullivan in February this year: "The World's Largest Oseltamivir Production Base," "The World's Highest Cumulative Five-Year Output of Oseltamivir," and "The World's Highest Cumulative Five-Year Shipment Volume of Oseltamivir." Since its establishment, Dongyang Light Pharmaceuticals has been driven by innovation and internationalization, leading the company’s development with outstanding commercialization capabilities. The company has deeply invested in R&D across three major therapeutic areas—infectious diseases, chronic diseases, and oncology—and currently holds over 140 approved drugs globally, with more than 100 drugs in the research pipeline, including over 40 innovative new drugs. Among these, three innovative drugs have been submitted for marketing approval, while ten are in clinical phases II and III. The company has filed over 2,400 patent applications, of which more than 1,300 have been granted. A team of over 1,200 researchers provides robust support for its product pipeline. It also operates a "National Key Laboratory for New Anti-Infective Drug Development" approved by the Ministry of Science and Technology, making it the first national-level corporate key laboratory in Dongguan.

As a leader and practitioner in the "AI for Science" research paradigm, DP Technology has published multiple related works in the field of drug design in international top journals. In April this year, DP Technology released the scientific large model system Deep Potential · Universe.^®, including DPA Molecular Simulation Large Model, Uni-Mol Molecular Conformation Large Model, Uni-Fold Protein Folding Large Model, Uni-RNA Gene Sequence Large Model, and Uni-SMART Scientific Literature Multimodal Large Model, etc. They not only reach SOTA levels in their respective fields but have also been integrated into DP Technology's product platform, bridging the "innovation to implementation" pathway. Particularly in the biopharmaceutical field, Hermite, developed by DP Technology based on AI for Science,^®Drug Calculation Design Platform, RiDYMO^®The difficult-to-drug target R&D platform has partnered with multiple clients, integrating the advanced AI for Science research paradigm more broadly into drug discovery. Through DP Technology's solutions, the platform enhances the R&D investment efficiency and decision-making quality of its partners.

About DP Technology

DP Technology is a global leader in AI for Science, which uses AI to learn a series of scientific principles and knowledge, and further addresses key issues in scientific research and industrial R&D.

Relying on deep cultivation in the field of interdisciplinary research, DP Technology has built the "Deep Potential·Universe" AI for Science large model system, further addressing key issues in scientific research and industrial development. This advancement transitions research methods across numerous disciplines from the "experimental trial-and-error/computational" era into the "pre-trained model era." It establishes an "innovation-to-application" pipeline and open ecosystem for AI for Science, constructs microscale industrial infrastructure based on AI for Science, and empowers "thousands of industries." This effort pioneers a new generation of industrial design and simulation systems for biomedical research, energy, materials, and information science and engineering — the most fundamental areas driving human economic development.

DP Technology is a national high-tech enterprise and a national specialized and new "little giant" enterprise, with research and development centers located in cities such as Beijing, Shanghai, and Shenzhen. The scientific research team is led by an academician of the Chinese Academy of Sciences, gathering over a hundred outstanding young scientists and engineers from various fields including mathematics, physics, chemistry, biology, materials, and computer science. Among them, the proportion of PhDs and postdoctoral researchers exceeds 35%. Core members have won the "Gordon Bell Prize," the highest award in the global high-performance computing field in 2020, and their related work was selected as one of China's top ten scientific advances in 2020 and one of the ten major technological breakthroughs in the global AI field.